Choosing Between Combination Therapy and Novel Jack Inhibitors in Myelofibrosis: balancing side effects and positive results

The 64th American Society of Hematology (ASH) Annual Meeting and Exposition took place on December 10-13, 2022, in New Orleans, LA, and saw leading experts from all over the world gather to showcase the latest research in hematological malignancies.

In this podcast, you will hear from experts Aaron Gerds, MD, Cleveland Clinic, Cleveland, OH, and Lucia Masarova, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, who discuss key updates in myeloproliferative neoplasms (MPNs) presented at this year’s meeting. Topics covered include updates from the MOMENTUM trial (NCT04173494), the importance of combination approaches, and novel agents being explored, including calreticulin (CALR)-targeting antibodies.

The post MPN highlights at ASH 2022: novel agents, combinations & the role of immunotherapy appeared first on VJHemOnc.